275 related articles for article (PubMed ID: 38187075)
1. Teplizumab in Type 1 Diabetes Mellitus: An Updated Review.
Thakkar S; Chopra A; Nagendra L; Kalra S; Bhattacharya S
touchREV Endocrinol; 2023 Nov; 19(2):22-30. PubMed ID: 38187075
[TBL] [Abstract][Full Text] [Related]
2. Teplizumab for treatment of type 1 diabetes mellitus.
Skelley JW; Elmore LK; Kyle JA
Ann Pharmacother; 2012 Oct; 46(10):1405-12. PubMed ID: 22968521
[TBL] [Abstract][Full Text] [Related]
3. Teplizumab: type 1 diabetes mellitus preventable?
Misra S; Shukla AK
Eur J Clin Pharmacol; 2023 May; 79(5):609-616. PubMed ID: 37004543
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Teplizumab for Treatment of Type One Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Nourelden AZ; Elshanbary AA; El-Sherif L; Benmelouka AY; Rohim HI; Helmy SK; Sayed MK; Ismail A; Ali AS; Ragab KM; Zaazouee MS
Endocr Metab Immune Disord Drug Targets; 2021; 21(10):1895-1904. PubMed ID: 33302842
[TBL] [Abstract][Full Text] [Related]
5. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC; Bundy BN; Long SA; Bluestone JA; DiMeglio LA; Dufort MJ; Gitelman SE; Gottlieb PA; Krischer JP; Linsley PS; Marks JB; Moore W; Moran A; Rodriguez H; Russell WE; Schatz D; Skyler JS; Tsalikian E; Wherrett DK; Ziegler AG; Greenbaum CJ;
N Engl J Med; 2019 Aug; 381(7):603-613. PubMed ID: 31180194
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of anti-CD3 monoclonal antibodies in delaying the progression of recent-onset type 1 diabetes mellitus: A systematic review, meta-analyses and meta-regression.
Ashraf MT; Ahmed Rizvi SH; Kashif MAB; Shakeel Khan MK; Ahmed SH; Asghar MS
Diabetes Obes Metab; 2023 Nov; 25(11):3377-3389. PubMed ID: 37580969
[TBL] [Abstract][Full Text] [Related]
7. Journey of Teplizumab: A Promising Drug in the Treatment of Type 1 Diabetes Mellitus.
Sharma N; Das DD; Chawla PA
Curr Diabetes Rev; 2024 Jan; ():. PubMed ID: 38279734
[TBL] [Abstract][Full Text] [Related]
8. Teplizumab Therapy to Delay the Onset of Type 1 Diabetes.
Novograd J; Frishman WH
Cardiol Rev; 2023 May; ():. PubMed ID: 37158990
[TBL] [Abstract][Full Text] [Related]
9. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N; Hagopian W; Ludvigsson J; Jain SM; Wahlen J; Ferry RJ; Bode B; Aronoff S; Holland C; Carlin D; King KL; Wilder RL; Pillemer S; Bonvini E; Johnson S; Stein KE; Koenig S; Herold KC; Daifotis AG;
Lancet; 2011 Aug; 378(9790):487-97. PubMed ID: 21719095
[TBL] [Abstract][Full Text] [Related]
10. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.
Ramos EL; Dayan CM; Chatenoud L; Sumnik Z; Simmons KM; Szypowska A; Gitelman SE; Knecht LA; Niemoeller E; Tian W; Herold KC;
N Engl J Med; 2023 Dec; 389(23):2151-2161. PubMed ID: 37861217
[TBL] [Abstract][Full Text] [Related]
11. Teplizumab therapy for type 1 diabetes.
Masharani UB; Becker J
Expert Opin Biol Ther; 2010 Mar; 10(3):459-65. PubMed ID: 20095914
[TBL] [Abstract][Full Text] [Related]
12. CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.
Chatenoud L; Waldmann H
Rev Diabet Stud; 2012; 9(4):372-81. PubMed ID: 23804274
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Herold KC; Gitelman S; Greenbaum C; Puck J; Hagopian W; Gottlieb P; Sayre P; Bianchine P; Wong E; Seyfert-Margolis V; Bourcier K; Bluestone JA;
Clin Immunol; 2009 Aug; 132(2):166-73. PubMed ID: 19443276
[TBL] [Abstract][Full Text] [Related]
14. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
Herold KC; Gitelman SE; Willi SM; Gottlieb PA; Waldron-Lynch F; Devine L; Sherr J; Rosenthal SM; Adi S; Jalaludin MY; Michels AW; Dziura J; Bluestone JA
Diabetologia; 2013 Feb; 56(2):391-400. PubMed ID: 23086558
[TBL] [Abstract][Full Text] [Related]
15. Role of Teplizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Managing Newly Diagnosed Type 1 Diabetes: An Updated Systematic Review and Meta-Analysis.
Kamrul-Hasan ABM; Mondal S; Nagendra L; Yadav A; Aalpona FTZ; Dutta D
Endocr Pract; 2024 May; 30(5):431-440. PubMed ID: 38519028
[TBL] [Abstract][Full Text] [Related]
16. Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function.
Fanaropoulou NM; Tsatsani GC; Koufakis T; Kotsa K
Expert Rev Clin Immunol; 2024 Feb; 20(2):185-196. PubMed ID: 37937833
[TBL] [Abstract][Full Text] [Related]
17. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function.
Herold KC; Gitelman SE; Gottlieb PA; Knecht LA; Raymond R; Ramos EL
Diabetes Care; 2023 Oct; 46(10):1848-1856. PubMed ID: 37607392
[TBL] [Abstract][Full Text] [Related]
18. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
Perdigoto AL; Preston-Hurlburt P; Clark P; Long SA; Linsley PS; Harris KM; Gitelman SE; Greenbaum CJ; Gottlieb PA; Hagopian W; Woodwyk A; Dziura J; Herold KC;
Diabetologia; 2019 Apr; 62(4):655-664. PubMed ID: 30569273
[TBL] [Abstract][Full Text] [Related]
19. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.
Vudattu NK; Herold KC
Expert Opin Biol Ther; 2014 Mar; 14(3):377-85. PubMed ID: 24517093
[TBL] [Abstract][Full Text] [Related]
20. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Webster AC; Wu S; Tallapragada K; Park MY; Chapman JR; Carr SJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD004756. PubMed ID: 28731207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
